Related Experiment Video
Updated: Jan 9, 2026
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
Published on: October 19, 2021
Meta-analysis of genetic mapping studies in mice reveals candidate epilepsy modifier genes that are outside the
Giovanna L Durante1,2, Anna L Tyler1, Rod C Scott3
1The Jackson Laboratory, Bar Harbor, Maine, USA.
Objective:
Despite decades of development in anti-seizure medications, ~30% of individuals remain refractory to all treatments, and none of the existing therapies are disease modifying. Identifying targets outside the current preclinical paradigm is critically important. This study aimed to characterize the landscape of current epilepsy treatments at the level of gene interaction networks and identify novel genetic modifiers of epilepsy as potential novel therapeutic targets.
Methods:
We performed a functional network analysis to score genes based on their interactions with known epilepsy genes, and we integrated these functional scores with population genetics data and drug tractability information. In parallel, we performed a meta-analysis of genome-wide association studies of epilepsy-related phenotypes in genetically diverse mice using a large compendium of historical phenotyping data. Genes within mapped loci were prioritized based on functional rankings, and genomic evolutionary rate profiling (GERP) was used to identify highly single-nucleotide polymorphisms at evolutionarily constrained positions.
Results:
Functional network analyses of known epilepsy genes revealed a strong involvement of neurodevelopmental processes in epilepsy pathogenesis, which are not targeted by existing or emerging treatments. Meta-analysis of seizure traits in mice identified 118 non-overlapping loci harboring potential seizure phenotype modifiers. Using functional rankings, we prioritized 168 candidate genes within these loci and used GERP scores to filter down to 75 SNPs as candidate variants within these genes. Among them, five genes-Ephb2, En2, Cadps2, Igsf21, and Cep170-contain regulatory variants in evolutionarily constrained sites. Four of these genes are validated as modifiers of neurological traits, including epilepsy susceptibility.
Significance:
This study prioritized epilepsy modifier genes that are strongly predicted to influence neurodevelopmental processes, which are underrepresented among current therapeutic targets. Furthermore, the identified genes represent novel candidate modifiers with potential clinical relevance. Our systems-level analysis offers a novel view into the potential target landscape, pointing toward promising new directions for disease-modifying treatments.
Insights
New research identifies novel epilepsy genes influencing neurodevelopment, offering potential targets for disease-modifying treatments. This study moves beyond current anti-seizure medications to explore new therapeutic avenues for refractory epilepsy.
Area of Science:
- Genetics
- Neuroscience
- Systems Biology
Background:
- Epilepsy affects millions, with ~30% of patients refractory to current anti-seizure medications.
- Existing epilepsy treatments are not disease-modifying, highlighting the need for novel therapeutic targets.
- Current preclinical research paradigms may not fully capture epilepsy's complexity.
Purpose of the Study:
- To analyze gene interaction networks of known epilepsy genes.
- To identify novel genetic modifiers of epilepsy for potential therapeutic targeting.
- To integrate functional network analysis with population genetics and drug tractability.
Main Methods:
- Functional network analysis to score genes based on interactions with known epilepsy genes.
- Integration of functional scores with population genetics and drug tractability data.
- Meta-analysis of genome-wide association studies in mice, prioritizing genes using functional rankings and GERP scores.
Main Results:
- Functional network analysis revealed neurodevelopmental processes are key in epilepsy pathogenesis, yet untargeted by current therapies.
- 118 loci associated with seizure phenotypes were identified in mice.
- 168 candidate genes were prioritized, leading to 75 single-nucleotide polymorphisms (SNPs) in evolutionarily constrained sites, including five genes with regulatory variants.
Conclusions:
- Identified epilepsy modifier genes strongly influence neurodevelopmental processes, which are underrepresented in current therapeutic targets.
- These genes represent novel candidates with potential clinical relevance for epilepsy.
- The systems-level analysis provides a new perspective on potential therapeutic targets for disease-modifying epilepsy treatments.
